+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 60 Pages
  • September 2026
  • GlobalData
  • ID: 4285658
Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Rohto Pharmaceutical Co Ltd (Rohto Pharmaceutical) manufactures and markets pharmaceutical products, cosmetics, and functional foods. The company offers products for eye care, skin care, internal medicine and other diseases. Under eyecare products, the company offers eye drops, contact lenses and eyewash. Under skincare products, the company offers face wash, creams, lotions, medicine and medicated products. It also offers medicines for internal use such as digestive products and herbal medicines. It has manufacturing and research laboratories in Iga, Osaka and Kyoto. The company along with its subsidiaries operates across the Americas, Asia, Japan, Oceania, Africa, and Europe. Rohto Pharmaceutical is headquartered in Osaka, Japan.

Rohto Pharmaceutical Co Ltd Key Recent Developments

  • Aug 06, 2026: Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027
  • May 13, 2026: Rohto Pharma: Consolidated Financial Results for the Fiscal Year Ended March 31, 2026
  • Mar 26, 2026: Rohto Eye Vision, Now Available, Featuring Japan’s Only BTA Formula That Focuses on Inflammation of Children’s Eyes
  • Mar 26, 2026: High Molecular Weight Chondroitin Over-The-Counter Eye Drops Containing 1% of [Ingredient Name] “V Rohto Dryguard Premium” New Release

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Rohto Pharmaceutical Co Ltd - Key Facts
  • Rohto Pharmaceutical Co Ltd - Key Employees
  • Rohto Pharmaceutical Co Ltd - Key Employee Biographies
  • Rohto Pharmaceutical Co Ltd - Major Products and Services
  • Rohto Pharmaceutical Co Ltd - History
  • Rohto Pharmaceutical Co Ltd - Company Statement
  • Rohto Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Rohto Pharmaceutical Co Ltd - Business Description
  • Business Segment: Eye Care Products
  • Overview
  • Performance
  • Business Segment: Medical
  • Performance
  • Business Segment: Oral medications/foods
  • Performance
  • Business Segment: Others
  • Overview
  • Performance
  • Business Segment: Skincare Products
  • Overview
  • Performance
  • Geographical Segment: America
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • R&D Overview
  • Rohto Pharmaceutical Co Ltd - Corporate Strategy
  • Rohto Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Rohto Pharmaceutical Co Ltd - Strengths
  • Rohto Pharmaceutical Co Ltd - Weaknesses
  • Rohto Pharmaceutical Co Ltd - Opportunities
  • Rohto Pharmaceutical Co Ltd - Threats
  • Rohto Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Rohto Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 06, 2026: Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027
  • May 13, 2026: Rohto Pharma: Consolidated Financial Results for the Fiscal Year Ended March 31, 2026
  • Mar 26, 2026: Rohto Eye Vision, Now Available, Featuring Japan’s Only BTA Formula That Focuses on Inflammation of Children’s Eyes
  • Mar 26, 2026: High Molecular Weight Chondroitin Over-The-Counter Eye Drops Containing 1% of [Ingredient Name] “V Rohto Dryguard Premium” New Release
  • Mar 16, 2026: Rohto Medical Business to Launch Wearable Medical Device for Managing Overactive Bladder Symptoms in the Chinese Market - Marking the First Step in Its Global Expansion of Its Medical Business.
  • Mar 10, 2026: Research Reveals the Involvement of Chondroitin Sulfate in Corneal and Conjunctival Inflammation Associated With Aging
  • Mar 09, 2026: Certified as a “Certified Health & Productivity Management Outstanding Organization (White 500)” for the 6th Consecutive Year and 9th Time Overall
  • Feb 12, 2026: Rohto Pharma: Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026
  • Feb 10, 2026: Announcement of Strengthened Collaboration With Reimei Toward Practical Application in the Field of Regenerative Medicine
  • Feb 10, 2026: Launch of Rohto Algard Epinastine Eye Drops
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • Rohto Pharmaceutical Co Ltd, Key Facts
  • Rohto Pharmaceutical Co Ltd, Key Employees
  • Rohto Pharmaceutical Co Ltd, Key Employee Biographies
  • Rohto Pharmaceutical Co Ltd, Major Products and Services
  • Rohto Pharmaceutical Co Ltd, History
  • Rohto Pharmaceutical Co Ltd, Other Locations
  • Rohto Pharmaceutical Co Ltd, Subsidiaries
  • Rohto Pharmaceutical Co Ltd, Key Competitors
  • Rohto Pharmaceutical Co Ltd, Ratios based on current share price
  • Rohto Pharmaceutical Co Ltd, Annual Ratios
  • Rohto Pharmaceutical Co Ltd, Interim Ratios
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Rohto Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Rohto Pharmaceutical Co Ltd, Performance Chart (2022 - 2026)
  • Rohto Pharmaceutical Co Ltd, Ratio Charts
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rohto Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Taisho Pharmaceutical Holdings Co Ltd
  • Daiichi Sankyo Co Ltd
  • Otsuka Pharmaceutical Co Ltd
  • Santen Pharmaceutical Co Ltd
  • Towa Pharmaceutical Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Shionogi & Co Ltd